ALSO NOTED: Rosetta expands U.S. operations; DOV announces Phase I results; and much more...

> Rosetta Genomics is expanding its U.S. operations. Release

> DOV Pharmaceutical announced Phase Ib results for DOV 21,947, its lead triple reuptake inhibitor for the treatment of depression and obesity. Release

> Pfizer is paring down its Ann Arbor campus. FiercePharma

> New insights into the way the brain operates are opening up a new therapeutic target to control fever as well as many of its symptoms like fatigue and loss of appetite. FierceBioResearcher

And Finally... J&J is suing the Red Cross. FiercePharma

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.